93 related articles for article (PubMed ID: 25057901)
1. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancreatic Cancer.
Lee MJ; Cho JY; Bae S; Jung HS; Kang CM; Kim SH; Choi HJ; Lee CK; Kim H; Jo D; Paik YK
J Proteome Res; 2024 Mar; 23(3):985-998. PubMed ID: 38306169
[TBL] [Abstract][Full Text] [Related]
3. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
[TBL] [Abstract][Full Text] [Related]
4. Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer.
Kojima K; Asmellash S; Klug CA; Grizzle WE; Mobley JA; Christein JD
J Gastrointest Surg; 2008 Oct; 12(10):1683-90. PubMed ID: 18709425
[TBL] [Abstract][Full Text] [Related]
5. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers.
Makawita S; Smith C; Batruch I; Zheng Y; Rückert F; Grützmann R; Pilarsky C; Gallinger S; Diamandis EP
Mol Cell Proteomics; 2011 Oct; 10(10):M111.008599. PubMed ID: 21653254
[TBL] [Abstract][Full Text] [Related]
6. Serum HSP70: a novel biomarker for early detection of pancreatic cancer.
Dutta SK; Girotra M; Singla M; Dutta A; Otis Stephen F; Nair PP; Merchant NB
Pancreas; 2012 May; 41(4):530-4. PubMed ID: 22158074
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of blood biomarker candidates for detection of pancreatic cancer.
Chen R; Crispin DA; Pan S; Hawley S; McIntosh MW; May D; Anton-Culver H; Ziogas A; Bronner MP; Brentnall TA
Pancreas; 2010 Oct; 39(7):981-8. PubMed ID: 20467349
[TBL] [Abstract][Full Text] [Related]
8. Advances in biomarker research for pancreatic cancer.
Bhat K; Wang F; Ma Q; Li Q; Mallik S; Hsieh TC; Wu E
Curr Pharm Des; 2012; 18(17):2439-51. PubMed ID: 22372502
[TBL] [Abstract][Full Text] [Related]
9. Personalized Graphene Oxide-Protein Corona in the Human Plasma of Pancreatic Cancer Patients.
Di Santo R; Digiacomo L; Quagliarini E; Capriotti AL; Laganà A; Zenezini Chiozzi R; Caputo D; Cascone C; Coppola R; Pozzi D; Caracciolo G
Front Bioeng Biotechnol; 2020; 8():491. PubMed ID: 32523944
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.
Lee T; Teng TZJ; Shelat VG
World J Gastrointest Surg; 2020 Dec; 12(12):468-490. PubMed ID: 33437400
[TBL] [Abstract][Full Text] [Related]
11. A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia.
Cavalcante Mde S; Torres-Romero JC; Lobo MD; Moreno FB; Bezerra LP; Lima DS; Matos JC; Moreira Rde A; Monteiro-Moreira AC
Biomark Res; 2016; 4():1. PubMed ID: 26823978
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics characterization of differential proteins in serum of mothers carrying Down syndrome fetuses: combining bioinformatics and ELISA.
Yu B; Zhang B; Shi Y; Shao SH; Wang QW; Huang RP; Yang YQ
Arch Med Sci; 2012 May; 8(2):183-91. PubMed ID: 22661988
[TBL] [Abstract][Full Text] [Related]
13. A Simple Clinical Scoring System to Determine the Risk of Pancreatic Cancer in the General Population.
Yoshimura D; Fukasawa M; Yoda Y; Ohtaka M; Ooka T; Takano S; Kawakami S; Fukasawa Y; Kuratomi N; Harai S; Shimamura N; Hasegawa H; Imagawa N; Suzuki Y; Yoshida T; Kobayashi S; Sato M; Yamaguchi T; Maekawa S; Enomoto N
Diagnostics (Basel); 2024 Mar; 14(6):. PubMed ID: 38535071
[TBL] [Abstract][Full Text] [Related]
14. An Overview of Genetic Changes and Risk of Pancreatic Ductal Adenocarcinoma.
Sarnecka AK; Zagozda M; Durlik M
J Cancer; 2016; 7(14):2045-2051. PubMed ID: 27877219
[TBL] [Abstract][Full Text] [Related]
15. Complement and Podocytopathies: Do We Have a New Biomarker?
Blasco M; Bomback AS
Kidney Int Rep; 2024 Mar; 9(3):520-522. PubMed ID: 38481505
[No Abstract] [Full Text] [Related]
16. Analysis of molecular pathways in pancreatic ductal adenocarcinomas with a bioinformatics approach.
Wang Y; Li Y
Asian Pac J Cancer Prev; 2015; 16(6):2561-7. PubMed ID: 25824797
[TBL] [Abstract][Full Text] [Related]
17. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.
Ormanns S; Siveke JT; Heinemann V; Haas M; Sipos B; Schlitter AM; Esposito I; Jung A; Laubender RP; Kruger S; Vehling-Kaiser U; Winkelmann C; Fischer von Weikersthal L; Clemens MR; Gauler TC; Märten A; Geissler M; Greten TF; Kirchner T; Boeck S
BMC Cancer; 2014 Aug; 14():624. PubMed ID: 25164437
[TBL] [Abstract][Full Text] [Related]
18. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.
Roy R; Zurakowski D; Wischhusen J; Frauenhoffer C; Hooshmand S; Kulke M; Moses MA
Br J Cancer; 2014 Oct; 111(9):1772-9. PubMed ID: 25137018
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.
Semrad T; Barzi A; Lenz HJ; Hutchins IM; Kim EJ; Gong IY; Tanaka M; Beckett L; Holland W; Burich RA; Snyder-Solis L; Mack P; Lara PN
Int J Clin Oncol; 2015 Jun; 20(3):518-24. PubMed ID: 25091263
[TBL] [Abstract][Full Text] [Related]
20. Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study.
Kim SH; Lee MJ; Hwang HK; Lee SH; Kim H; Paik YK; Kang CM
Cancer Biomark; 2019; 24(3):335-342. PubMed ID: 30829612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
